Business Context and Reporting Period
Company: Niagen Bioscience, Inc. (NAGE)
Filing Type: Form 8-K (Current Report)
Date of Report: March 4, 2026
Reporting Period: Fourth quarter and full year ended December 31, 2025.
The Company announced its financial results for the specified period via a press release furnished as Exhibit 99.1 and released a corporate presentation as Exhibit 99.2.
Key Financial Metrics
The provided Form 8-K text serves as a notification of the release of financial results and does not contain specific numerical data.
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Investors must refer to the attached press release (Exhibit 99.1) and earnings presentation (Exhibit 99.2) for detailed financial figures.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. It only confirms the issuance of results for the fourth quarter and year ended December 31, 2025.
Guidance, Outlook, and Risks
Management Commentary: The Company released a corporate presentation (Exhibit 99.2) which likely contains management commentary, outlook, and guidance, but the specific content is not included in the 8-K text.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text. The filing includes standard disclaimers stating that the information in Items 2.02 and 7.01 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for Q4 and FY 2025.
- Examine Exhibit 99.2 (Earnings Presentation) for forward-looking guidance, strategic updates, and management commentary.
- Verify year-over-year and quarter-over-quarter performance metrics not present in this summary.
- Check for any non-GAAP reconciliations or unusual items detailed in the attached exhibits.